UBS and Goldman Sachs Warn of Generic Drug Tariff Impact on India's Pharma Industry
Miles Bennett
Trump announced 100%-200% tariffs on imported generics starting 2028, targeting India — which supplies roughly 40% of US generic drugs; UBS and Goldman both warned that pure-export Indian drugmakers face an existential threat.
What do these tariffs actually do?
Trump set a two-year runway: 100% tariffs on imported generics from August 2028, rising to 200% in August 2029, with the stated goal of reshoring production.
Generics — cheaper versions of drugs whose patents have expired — account for roughly 90% of US prescriptions. About 40% of those come from India, covering essentials like blood-pressure, diabetes, and cancer medications.
This means → the policy targets not a handful of companies but the single largest source country in America's generic-drug supply chain.
Can reshoring actually happen this fast?
Namit Joshi, head of India's Pharmaceuticals Export Promotion Council, said building a full domestic US generics ecosystem would take at least four to five years.
Indian manufacturers hold a 30%-50% cost advantage over US-based production — a structural gap built over decades, not something a tariff decree can close overnight.
In plain terms = the US currently lacks both the factory capacity and the cost structure to replace Indian supply. Two years is nowhere near enough.
How does UBS read the situation for Indian drugmakers?
UBS analyst Aditi Samajpati wrote that Indian pharma companies are "on alert" — their drug exports to the US hit $9.7 billion in fiscal year 2024-25, reflecting heavy dependence on the American market.
She flagged three layers of uncertainty: past tariff threats that never materialized; a February bilateral negotiation that already produced a deal on generics; and India's cost advantage, which makes short-term supply-chain substitution unlikely.
This reflects UBS's core call: the probability of full implementation is itself in question, and markets should not price in the worst-case scenario linearly.
Which companies does Goldman consider relatively safe?
Goldman analyst Matt Dellatorre identified three names with relative advantage: Amneal (AMRX) — already has significant US-based infrastructure; Teva (TEVA) — diversified manufacturing footprint plus a branded-drug portfolio; Viatris (VTRS) — diversified manufacturing with limited direct US-market exposure.
This means → Goldman's filter comes down to one question: does the company have its own US capacity or a branded-drug moat?
In plain terms = companies that rely purely on bulk generic exports from India with no US manufacturing presence are the dead center of the tariff's target zone.
What do stock moves and corporate responses tell us?
After the announcement, Lupin fell 4%; Natco Pharma and Granules India dropped over 2.5%; Dr. Reddy's, Aurobindo Pharma, and Wockhardt each fell more than 1.5%.
Independent pharma consultant Salil Kallianpur was blunt: slapping 100%-200% tariffs on products with single-digit margins "is essentially a de-listing notice."
Some large Indian drugmakers had already moved: Sun Pharma spent $11.75 billion acquiring New Jersey-based Organon; Zydus Lifesciences paid nearly $300 million for a French orthopedic-device maker and another $125 million for two US biologics manufacturing facilities. This reflects a playbook of buying onshore capacity and high-value product lines rather than waiting for tariffs to hit.
What should markets watch over the next two years?
Whether the tariffs ultimately take effect — and how exemptions are drawn — remains the core variable for the sector.
India's 30%-50% cost advantage is the hardest structural factor in this reshoring contest; even if tariffs land in full, the US cannot replicate that cost structure in the short term.
In plain terms = this is a tug-of-war between policy ambition and industrial reality. Who blinks first, and by how much, determines how the cost is split between Indian drugmakers and American consumers.
Content is for reference only, not financial advice.